| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC2785 |
| Trial ID | NCT05037669 |
| Disease | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | PACE CAR-T19 |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Withdrawn |
| Title | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma |
| Year | 2021 |
| Country | United States |
| Company sponsor | University of Pennsylvania |
| Other ID(s) | UPCC 27419 |
| Vector information | |||||||
|
|||||||
| Cohort 1 | |||||||||
|
|||||||||